news

FDA sends warning letter to company illegally selling CBD products

1
SHARES

A business selling unapproved products containing CBD has been sent a warning letter from the FDA and FTC for making unsubstantiated claims about their therapeutic properties.

The US Food and Drug Administration (FDA) and the US Federal Trade Commission (FTC) have sent a joint warning letter to Rooted Apothecary for illegally selling unapproved products containing cannabidiol (CBD).

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The products were sold online with unsubstantiated claims that they could treat teething pain and earaches in infants, autism, attention-deficit/hyperactivity disorder (ADHD), Parkinson’s and Alzheimer’s, as well as other conditions.

The FTC is also concerned that one or more of the efficacy claims made by the company is not supported by competent and reliable scientific evidence such as human clinical trials.

The products are also misbranded, according to the Federal Food, Drug, and Cosmetic (FD&C) Act, as their labelling fails to include adequate directions for use.

The products are also misbranded… as their labelling fails to include adequate directions for use”

“Cannabis and cannabis-derived compounds are subject to the same laws and requirements as FDA-regulated products that contain any other substance. We are working to protect Americans from companies marketing products with unsubstantiated claims that they prevent, diagnose, treat or cure a number of diseases or conditions. This is especially concerning when companies are peddling unproven CBD products for use in vulnerable populations like infants and children,” said Acting FDA Commissioner Ned Sharpless.

The FDA and FTC have requested that the company responds within 15 working days with a proposal to correct the violations. Failure to correct these could result in legal action.

Share via
Share via